Is Primary Biliary Cholangitis on Your Radar?

Nov 10 2023
Room 210 - Hynes Convention Center
12:30 - 2:00 PM EST

Description

Supported by: CymaBay Therapeutics

Organized by: Medscape Education

Presenters:

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD

Gideon Hirschfield, MB BChir, PhD, FRCP

Marlyn J. Mayo, MD

Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune disease of the liver, which, if undertreated, can progress to cirrhosis, liver failure, and death. FDA-approved treatment options for PBC are presently limited, and many patients do not have an adequate response to first- and second-line therapies and/or experience adverse effects that limit their use and impair patients’ quality of life. A new generation of PBC therapies with novel mechanisms of action are in late-stage development. In this live, interactive, case-based symposium, expert faculty will review the latest information on the diagnosis and management of PBC and will delve into clinical evidence for emerging therapies. Patient cases will provide clinical context and useful pointers for clinical decision-making in PBC management.

Learning Objectives: Upon completion of this activity, participants will:

  1. Have increased knowledge regarding the impact and burden of PBC on patients’ quality of life and data on emerging targeted PBC treatments
  2. Have greater competence related to diagnosing PBC in accordance with evidence-based criteria
  3. Demonstrate greater confidence in their ability to implement PBC treatments that address patients’ symptoms

CME Hours: Maximum of 1.5 AMA PRA Category 1 Credit(s)

For more information and to register, visit: https://www.medscape.org/symposium/pbc-2023